SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Sequenom, Inc. Announces Date Of First Quarter 2014 Financial Results And Conference Call

SAN DIEGO, April 17, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2014 after closing of the NASDAQ Global Market on Thursday, May 1, 2014.

A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Sequenom Web site. 

To access the live teleconference call, dial 877-883-0383 in the U.S. and Canada, and 412-902-6506 for other international callers. Please use code 4130222. For interested parties unable to listen to the live webcast, a teleconference replay will be available through Friday, May 16, 2014. The replay will be accessible by dialing 877-344-7529 or 412-317-0088 internationally, and entering the conference number 10044794.

The conference call webcast is accessible through the "Investors" section of the Sequenom Web site at www.sequenom.com/invest. An online replay will be available following the initial broadcast until Friday, May 16, 2014. 

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. Website: http://www.sequenom.com/

SEQUENOM logo.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.